Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience
- 9 October 2021
- journal article
- research article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 22 (4), 260-269
- https://doi.org/10.1016/j.clml.2021.09.022
Abstract
No abstract availableThis publication has 32 references indexed in Scilit:
- What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancerGenes & Development, 2013
- Adverse impact of IDH1 and IDH2 mutations in primary AML: Experience of the Spanish CETLAM groupLeukemia Research, 2012
- Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid LeukemiaThe New England Journal of Medicine, 2012
- The prognostic significance of IDH2 mutations in AML depends on the location of the mutationBlood, 2011
- Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic valueBlood, 2010
- Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemiaBlood, 2010
- IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B StudyJournal of Clinical Oncology, 2010
- Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete RemissionJAMA, 2009
- HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation CyclophosphamideTransplantation and Cellular Therapy, 2008
- A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing RiskThe Annals of Statistics, 1988